TrialJournal of clinical pharmacology2018

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.

Christian Schwabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.